Diseases & Conditions
Grants & Contracts
News & Events
See the list of featured NIAID clinical trials below or view the complete list of NIAID studies recruiting participants on ClinicalTrials.gov.
This 10- to 20-minute survey is available for patients with eczema or parents of patients with eczema. These questions will help us learn more about patient experiences to improve current research and guide future research.
NIAID is committed to advancing the understanding of how and why autoimmune diseases such as rheumatoid arthritis occur.
This trial is a randomized, double-blind, placebo controlled trial designed to test whether two years treatment of preschool children aged 2-3 years of age at high risk for asthma with omalizumab (anti-IgE) for two years will prevent the progression to childhood asthma, as reflected by a reduction in the prevalence of active asthma in the Final 12 months during 2 year observation period off study drug.
This study will determine the long term medical condition and daily functioning of participants with CGD after a transplant and if possible, compare these results to participants who do not undergo a transplant.
The primary purpose of NIAID's ACTIV-5/BET study is to evaluate the efficacy of investigational therapeutics in adults hospitalized for COVID-19.
The goal of this study is to enhance understanding of the demographic, immunologic, and metabolic characteristics of individuals at risk for developing type 1 diabetes.
This study is trying to see whether taking an HCV treatment with fewer clinic visits and laboratory tests can cure just as many people as the standard approach that uses more visits and laboratory tests.
HIV remains a major health issue globally and within the United States. Recent audience research found that many Americans are not aware that HIV is still a health issue in the U.S., are unsure if they might be vulnerable to exposure, and do not know if there is a cure.
This study will evaluate the safety and efficacy of the injectable drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected cisgender men and transgender women who have sex with men (MSM and TGW).